SkinJect said it raised nearly $3 million for the patch it’s developing to treat skin cancers.
The $2.5 million equity round, revealed yesterday in a regulatory filing, involved 13 unnamed investors, Pittsburgh-based SkinJect said.
Get the full story on our sister site, Drug Delivery Business.